Trial data for Corcept’s relacorilant, Korlym expected next year
The Phase 3 GRACE trial testing relacorilant in people with Cushing’s syndrome has completed enrollment and data from it is expected next year, according to a recent corporate update from Corcept Therapeutics, its developer. The company plans to submit a new drug application (NDA) to U.S. authorities to market…